WaveWriter Alpha™ SCS System Launch Events
Recordings Now Available
WaveWriter Alpha™ SCS System Launch Events
Recordings Now Available
Hear about the latest spinal cord stimulation (SCS) advancement in chronic pain therapy from Boston Scientific tailored to meet physicians’ and patients’ needs at every point in the pain management journey. WaveWriter Alpha is the first SCS portfolio designed to deliver FAST™ – Fast-Acting Sub-perception Therapy targeting a new and distinct mechanism of action in SCS1.
Access recordings of the WaveWriter Alpha virtual education sessions or register for upcoming event featuring esteemed leaders in neuromodulation:
Hear about the latest spinal cord stimulation (SCS) advancement in chronic pain therapy from Boston Scientific tailored to meet physicians’ and patients’ needs at every point in the pain management journey. WaveWriter Alpha is the first SCS portfolio designed to deliver FAST™ – Fast-Acting Sub-perception Therapy targeting a new and distinct mechanism of action in SCS1.
Access recordings of the WaveWriter Alpha virtual education sessions or register for upcoming event featuring esteemed leaders in neuromodulation:
1. FAST MOA based on computational modeling from Dr. Warren Grill’s lab at Duke University. Gilbert et al., Computational modeling predicts dorsal columns are involved in fast-acting sub-perception spinal cord stimulation (SCS). SFN 2021
The information presented is for discussion purposes only and does not constitute reimbursement or legal advice.
US Indications for Use: The Boston Scientific Spinal Cord Stimulator Systems are indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs including unilateral or bilateral pain associated with the following: failed back surgery syndrome, Complex Regional Pain Syndrome (CRPS) Types I and II, intractable low back pain and leg pain. Associated conditions and etiologies may be: radicular pain syndrome, radiculopathies resulting in pain secondary to failed back syndrome or herniated disc, epidural fibrosis, degenerative disc disease (herniated disc pain refractory to conservative and surgical interventions), arachnoiditis, multiple back surgeries. Contraindications, warnings, precautions, side effects. The SCS Systems are contraindicated for patients who: are unable to operate the SCS System, have failed trial stimulation by failing to receive effective pain relief, are poor surgical risks, or are pregnant. Refer to the Instructions for Use provided with the SCS System or Pain.com for potential adverse effects, warnings, and precautions prior to using this product. Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.
Subperception stimulation has been demonstrated to be safe and effective in patients who have been treated successfully with conventional, paresthesia-inducing stimulation for at least six months. Full stimulation parameter ranges and options for both paresthesia based and subperception therapy are available for clinician’s use throughout the patient’s experience and treatment with SCS.
© 2021 Boston Scientific Corporation or its affiliates. All rights reserved. NM-980310-AA
1. FAST MOA based on computational modeling from Dr. Warren Grill’s lab at Duke University. Gilbert et al., Computational modeling predicts dorsal columns are involved in fast-acting sub-perception spinal cord stimulation (SCS). SFN 2021
The information presented is for discussion purposes only and does not constitute reimbursement or legal advice.
US Indications for Use: The Boston Scientific Spinal Cord Stimulator Systems are indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs including unilateral or bilateral pain associated with the following: failed back surgery syndrome, Complex Regional Pain Syndrome (CRPS) Types I and II, intractable low back pain and leg pain. Associated conditions and etiologies may be: radicular pain syndrome, radiculopathies resulting in pain secondary to failed back syndrome or herniated disc, epidural fibrosis, degenerative disc disease (herniated disc pain refractory to conservative and surgical interventions), arachnoiditis, multiple back surgeries. Contraindications, warnings, precautions, side effects. The SCS Systems are contraindicated for patients who: are unable to operate the SCS System, have failed trial stimulation by failing to receive effective pain relief, are poor surgical risks, or are pregnant. Refer to the Instructions for Use provided with the SCS System or Pain.com for potential adverse effects, warnings, and precautions prior to using this product. Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.
Subperception stimulation has been demonstrated to be safe and effective in patients who have been treated successfully with conventional, paresthesia-inducing stimulation for at least six months. Full stimulation parameter ranges and options for both paresthesia based and subperception therapy are available for clinician’s use throughout the patient’s experience and treatment with SCS.
© 2021 Boston Scientific Corporation or its affiliates. All rights reserved. NM-980310-AA